Moderna stock toppled Thursday after the biotech company's experimental CMV vaccine failed in a Phase 3 study of 7,500 women. The post Moderna Topples, Threatening Its 50-Day Line, After A Key Vaccine Bites The Dust appeared first on Investor's Business Daily.
Continue reading...
Continue reading...